A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
University Hospital, Geneva
Emory University
Critical Outcome Technologies Inc.
City of Hope Medical Center